Liver Cancer
Copyright ©The Author(s) 2004.
World J Gastroenterol. Dec 1, 2004; 10(23): 3419-3423
Published online Dec 1, 2004. doi: 10.3748/wjg.v10.i23.3419
Figure 2
Figure 2 Dose-dependent suppression of the formation of rGST P-positive foci by rosiglitazone. As clearly demonstrated, Rosi suppressed the formation of rGST P-positive foci in a dose-dependent manner within the range of 0.88-500 ppm in diet (aP < 0.05, bP < 0.01).